Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sprycel in Polycythemia Vera
NCT00538980Phase 2Terminated
- Sponsor
- Weill Cornell Medicine
- Start
- Apr 2007
- Primary completion
- Aug 2010
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in polycythemia vera (PV), sponsored by Weill Cornell Medicine. Started Apr 2007; status: terminated.
02
Drugs
dasatinib
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on NCT00538980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00538980.